Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Net Income towards Common Stockholders: 2015-2025

Historic Net Income towards Common Stockholders for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$11.2 million.

  • Spyre Therapeutics' Net Income towards Common Stockholders rose 83.80% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 30.68%. This contributed to the annual value of -$208.0 million for FY2024, which is 38.60% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Net Income towards Common Stockholders of -$11.2 million as of Q3 2025, which was up 69.54% from -$36.7 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Net Income towards Common Stockholders ranged from a high of -$11.2 million in Q3 2025 and a low of -$217.1 million during Q2 2023.
  • In the last 3 years, Spyre Therapeutics' Net Income towards Common Stockholders had a median value of -$43.9 million in 2024 and averaged -$58.1 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Net Income towards Common Stockholders tumbled by 872.45% in 2023, and later skyrocketed by 83.80% in 2025.
  • Spyre Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$20.4 million in 2021, then increased by 7.94% to -$18.8 million in 2022, then slumped by 235.67% to -$63.2 million in 2023, then grew by 10.90% to -$56.3 million in 2024, then spiked by 83.80% to -$11.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$11.2 million for Q3 2025, versus -$36.7 million for Q2 2025 and -$44.8 million for Q1 2025.